Boeing
BA
$172.65
+3.30%
Boeing is a global aerospace and defense prime operating three segments — Commercial Airplanes (which generated roughly $11.75B of the most recent quarterly revenue), Defense, Space & Security (~$7.48B), and Global Services (~$5.34B) — building commercial jets seating more than 130 passengers, military aircraft, satellites, and aftermarket support services. As one of only two Western duopoly-scale commercial airframers alongside Airbus, Boeing's competitive identity rests on its narrowbody and widebody backlogs, its entrenched defense franchise, and a high-margin services annuity that partially offsets the cyclicality of aircraft delivery cycles. The current investor narrative is a classic turnaround debate: bulls point to FAA certification of the 737 MAX 10 as a major regulatory overhang removed, new labor contracts signed with its machinists, and defense contract wins as catalysts for cash flow and margin recovery into 2027, while bears emphasize persistent quarterly losses, a deeply levered balance sheet, and execution risk versus a resurgent Airbus and SpaceX. Recent headlines capture this tension — coverage ranges from "Great News for Boeing Investors" on certification to pieces framing Boeing as a "classic turnaround play with lingering execution risks" and noting the stock fell back below $200 ahead of a strike deadline before new contracts were signed.…
BA
Boeing
$172.65
Related headlines
Investment Opinion: Should I buy BA Today?
Rating: Hold with a speculative buy bias for risk-tolerant investors. The core thesis is that Boeing is a levered turnaround where MAX 10 certification and delivery ramp can drive a 2027 earnings recovery, but current quarterly losses and a 50.1x forward PE mean the stock is priced for success. The analyst consensus is 'buy' with a mean rating of 1.52 and an average target of $267.22, implying +41.9% upside, but the wide target range ($206–$305) signals uncertainty.
Supporting evidence includes revenue growth of 7.96% YoY to $24.56B in Q2 2026, a positive free cash flow inflection of +$631M in Q2, and a services segment ($5.34B) providing higher-margin ballast. However, profitability remains fragile with a Q2 net loss of -$444M and gross margin of 9.83%, while the balance sheet carries 9.98x debt-to-equity and a 0.33 quick ratio. The valuation is a recovery premium: 50.1x forward PE and 28.4x EV/EBITDA versus mature primes in the mid-to-high teens, justified only if consensus FY EPS of $14.56 materializes.
Key risks that could invalidate the thesis are a delay in MAX 10 delivery ramp, further margin compression below 9%, and a liquidity crunch from negative free cash flow. The rating would upgrade to Buy if gross margins sustainably exceed 12% and free cash flow turns positive for two consecutive quarters, or downgrade to Sell if revenue growth decelerates below 5% or the stock breaks below the $176.77 52-week low. Relative to its own history, the stock appears near the low end of its multi-year valuation range, suggesting the market has priced in substantial pessimism — but the premium to peers on EBITDA means it is not cheap on absolute terms.
Sign up to view all
BA 12-Month Price Forecast
Boeing presents a balanced risk/reward: the stock is deeply oversold (down 17.31% YTD, near the bottom of its 52-week range) and analyst targets imply significant upside, but the valuation already prices a recovery that has yet to show durable margin improvement. The MAX 10 certification and positive Q2 free cash flow are encouraging, but the levered balance sheet and thin margins leave little room for error. I would upgrade to bullish if gross margins sustainably exceed 12% and free cash flow remains positive for two quarters, or downgrade to bearish if the stock breaks below $176.77 or revenue growth decelerates below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boeing's 12-month outlook, with a consensus price target around $237.42 and implied upside of +37.5% versus the current price.
Average Target
$237.42
0 analysts
Implied Upside
+37.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$157 - $305
Analyst target range
Coverage is robust with 27 analysts, and sentiment is decisively bullish: the consensus recommendation is "buy" with a mean rating of 1.52 (where 1.0 is a strong buy), and the average target price of $267.22 implies roughly +41.9% upside from the current $188.35 — a striking disconnect between Wall Street's optimism and the market's pessimism. The consensus leans clearly bullish, and the institutional ratings flow supports it: Argus Research upgraded to Buy from Hold on August 11, BNP Paribas upgraded to Outperform from Underperform on August 3, and Jefferies, BofA, Tigress, JPMorgan, and RBC all reiterated Buy/Outperform/Overweight ratings through September — a pattern of upgrades and reaffirmations rather than downgrades.
The target range of $206.00 to $305.00 is wide — a spread of about 48% of the low end — signaling meaningful uncertainty about the pace of the turnaround. The high target of $305 assumes successful MAX 10 ramp, margin expansion toward historical mid-teens gross margins, and multiple expansion as earnings normalize toward the $14.56 consensus EPS; the low target of $206 (still ~9.4% above the current price) prices in continued execution friction, margin compression, and slower cash flow recovery but no catastrophic outcome. Notably, even the lowest analyst target sits above the current price, suggesting the sell-off has overshot fundamental expectations — though the wide dispersion and the stock's -26.64% relative underperformance versus SPY over the past year indicate the market is demanding proof before re-rating the shares.
Bulls vs Bears: BA Investment Factors
The bear case currently has stronger near-term evidence: Boeing is posting quarterly losses (-$444M in Q2 2026), carries 9.98x debt-to-equity, and trades at a 50.1x forward PE that demands an earnings recovery not yet visible in margins. However, the bull case is building — MAX 10 certification, positive Q2 free cash flow of $631M, and a 42% analyst target upside suggest the pessimism may be overdone. The single most important tension is whether the MAX 10-driven delivery ramp converts into durable mid-teens gross margins and positive free cash flow by 2027; if it does, the recovery premium is justified, but if execution slips, the levered balance sheet leaves little downside cushion.
Bullish
- Wall Street sees 42% upside: The 27-analyst consensus is 'buy' with a mean rating of 1.52 and an average target of $267.22, implying +41.9% upside from $188.35. Even the lowest target of $206 sits 9.4% above the current price, suggesting the sell-off has overshot fundamental expectations.
- MAX 10 certification removes overhang: FAA certification of the 737 MAX 10 eliminates a major regulatory uncertainty that has capped the stock, unlocking near-term cash flow and margin expansion expected to materialize by 2027. This is the single largest catalyst for converting Boeing's backlog into revenue.
- Revenue recovery is underway: Q2 2026 revenue of $24.56B rose 7.96% year-over-year from $22.75B, with sequential growth from $22.22B in Q1 2026 and $23.95B in Q4 2025. The delivery ramp is translating into steady top-line improvement across Commercial Airplanes ($11.75B), Defense ($7.48B), and Services ($5.34B).
- Free cash flow inflection in Q2: Q2 2026 free cash flow turned positive at +$631M on operating cash flow of $1.36B, a sharp reversal from -$1.45B in Q1 2026 and -$1.18B in Q4 2025. If sustained, this marks the beginning of the cash generation recovery that the valuation requires.
Bearish
- Deeply levered balance sheet: Debt-to-equity stands at 9.98x with total debt at 88.3% of capitalization, a current ratio of 1.19, and a quick ratio of just 0.33. Interest expense of $600M in Q2 alone consumes cash, and the $7.24B cash balance leaves limited room for error.
- Persistent quarterly losses: Q2 2026 net income was -$444M (EPS -$0.67), deteriorating from Q1 2026's -$4M, with gross margin compressed to 9.83% from 11.46% in Q1 and 10.70% in Q2 2025. The trailing net margin of 2.50% and operating margin of 4.79% remain thin for an aerospace prime.
- Valuation prices a recovery: The forward PE of 50.1x, EV/EBITDA of 28.4x, and price-to-cash-flow of 155.4x sit at a premium to mature primes trading in the mid-to-high teens on EBITDA. The market is paying for a dramatic earnings recovery to consensus FY EPS of $14.56 from a current run-rate loss.
- Falling-knife technical profile: The stock is down 17.31% YTD and 18.97% over six months, sitting at just 14.9% of its 52-week range ($176.77–$254.35) with a max drawdown of -26.87%. Relative strength versus SPY is -26.64% over one year and -28.76% YTD, showing persistent underperformance.
BA Technical Analysis
Boeing is in a sustained, broad downtrend: the stock is down 13.51% over the past year, 17.31% year-to-date, and 18.97% over six months, with the current price of $188.35 sitting at just 14.9% of its 52-week range of $176.77–$254.35 — essentially pinned near the lows rather than the highs. That positioning signals a falling-knife profile rather than a momentum extension: the stock has given back nearly all of its 52-week advance and is testing the bottom of its annual range, with a max drawdown of -26.87% underscoring how punishing the decline has been. Relative strength confirms the underperformance, with a 1-year relative strength versus SPY of -26.64% and a YTD spread of -28.76% against a market that rose 11.45% YTD.
Short-term momentum is negative and, importantly, decelerating rather than stabilizing: the stock is down 5.79% over the past month and 10.10% over three months, both worse than the 1-year decline of 13.51% on an annualized basis, meaning the pace of selling has intensified recently. This is a bearish divergence from an already weak long-term trend — the 1-month relative strength of -4.77% versus SPY's -1.02% shows Boeing lagging even a soft tape, and the 3-month relative strength of -12.95% versus SPY's +2.85% highlights a widening gap. The most recent action — a bounce from the $184.39 low on September 28 to $188.35, with a modest +0.43% single-day gain on volume of 6.58M shares — looks like tentative stabilization rather than a confirmed reversal, and without RSI data the price structure alone suggests oversold conditions that have yet to produce a durable turn.
Key technical levels are clearly defined: support sits at the 52-week low of $176.77, roughly 6.1% below the current $188.35, while resistance is the 52-week high of $254.35, about 35% above — a wide, asymmetric risk/reward band that reflects how far the stock has fallen. A breakdown below $176.77 would signal capitulation and likely open a new leg lower, whereas reclaiming the $200 psychological level and then the $220–$230 congestion zone (where the stock traded repeatedly in mid-2026) would be the first evidence of a trend change. With a beta of 1.257, Boeing is roughly 26% more volatile than the market, meaning position sizing should account for amplified drawdowns — a 1% SPY move implies roughly a 1.26% BA move, and the -26.87% max drawdown illustrates the tail risk of holding through unresolved execution issues.
Beta
1.26
1.26x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$165-$254
Price range past year
Annual Return
-19.2%
Cumulative gain past year
| Period | BA Return | S&P 500 |
|---|---|---|
| 1m | -8.0% | +0.7% |
| 3m | -20.1% | +3.0% |
| 6m | -24.1% | +6.8% |
| 1y | -19.2% | +11.9% |
| ytd | -24.2% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BA Fundamental Analysis
Revenue is growing but from a depressed base: Q2 2026 revenue of $24.56B rose 7.96% year-over-year versus $22.75B in Q2 2025, and the sequential trend is constructive — $22.22B in Q1 2026 and $23.95B in Q4 2025 — pointing to steady recovery in deliveries. Segment data shows Commercial Airplanes at $11.75B, Defense, Space & Security at $7.48B, and Global Services at $5.34B, with the commercial segment the largest swing factor and services providing a steadier, higher-margin ballast. The growth trajectory implies the investment case hinges on delivery ramp and MAX 10 certification converting backlog into revenue, but the 7.96% growth rate is modest for a recovery story and leaves little cushion if execution slips.
Profitability remains fragile: Q2 2026 net income was -$444M (EPS -$0.67), a deterioration from Q1 2026's near-breakeven -$4M, and gross margin compressed to 9.83% from 11.46% in Q1 and 10.70% in Q2 2025. The trailing net margin of 2.50% and operating margin of 4.79% are thin for an aerospace prime, and the Q4 2025 net income of $8.22B was an anomaly driven by a $9.13B non-operating gain (other income) rather than operations — operating income that quarter was actually -$815M. The path to profitability is uneven: Q1 2026 operating income of $448M showed progress, but Q2's $78M operating income and negative pre-tax result (-$365M) signal that margin recovery is not yet durable, and gross margins in the high single digits remain well below the mid-teens typical of a healthy airframe cycle.
Balance sheet leverage is the central financial risk: debt-to-equity stands at 9.98x, total debt to capitalization at 88.3%, and the current ratio is a thin 1.19 with a quick ratio of just 0.33 — liquidity is adequate but not comfortable. Free cash flow is deeply challenged, with TTM FCF of -$210M, Q1 2026 FCF of -$1.45B, and Q4 2025 FCF of -$1.18B, though Q2 2026 turned positive at +$631M on operating cash flow of $1.36B, a hopeful inflection. ROE of 40.98% is distorted by a near-zero or negative equity base (equity multiplier of ~27x), so it is not a meaningful quality signal; the real read is that Boeing still depends on external financing and working-capital management to fund operations, and the $7.24B cash balance against heavy debt service (interest expense of $600M in Q2 alone) leaves limited room for error.
Quarterly Revenue
$24.6B
2026-06
Revenue YoY Growth
+8.0%
YoY Comparison
Gross Margin
9.8%
Latest Quarter
Free Cash Flow
$-210000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BA Overvalued?
Because trailing net income is marginally positive (EPS of $0.0135, net margin 2.50%) but economically meaningless at this scale, the PE ratio of 87.2x is distorted and I lead instead with the forward PE of 50.1x and the PS ratio of 1.85x as the more informative metrics — the forward multiple implies the market expects a dramatic earnings recovery, with consensus FY EPS of $14.56 versus the current run-rate loss. The gap between the 87.2x trailing and 50.1x forward PE is enormous, signaling that the market is pricing in a sharp 2027 earnings inflection tied to MAX 10 certification and delivery ramp; the EV/Sales of 1.89x and EV/EBITDA of 28.4x further confirm the stock is valued on recovery, not current profitability.
Against aerospace and defense peers, Boeing screens expensive on most multiples: a PS of 1.85x is not extreme in absolute terms, but the 50.1x forward PE and 28.4x EV/EBITDA sit at a premium to a sector where mature primes typically trade in the mid-to-high teens on EBITDA, and the 30.3x price-to-book is inflated by a near-zero equity base rather than by premium returns. The premium is only justifiable if Boeing delivers the earnings recovery embedded in consensus — the PEG ratio of -0.77 is negative and therefore uninformative given the loss-making base, and the 155.4x price-to-cash-flow ratio underscores how far cash generation must improve to support the valuation. In short, the market is paying a recovery premium for a company still posting quarterly losses, which leaves the stock vulnerable to any execution disappointment.
Historically, Boeing's PS ratio has ranged from roughly 4.5x to 8.5x over the past several years (e.g., 8.34x in Q4 2024, 5.27x in Q3 2024, 6.97x in Q2 2026 on the historical-ratio series), so the current 1.85x PS on the live valuation data appears dramatically below its own band — but this discrepancy reflects differing share-count and market-cap bases across data sources rather than a genuine 75% de-rating, and investors should treat the historical series as directional only. What is clear is that the stock has de-rated alongside the price decline (down 17.31% YTD), and the current valuation sits closer to the low end of its multi-year range than the high end, implying the market has already priced in substantial pessimism — a potential value opportunity if the turnaround materializes, or a value trap if margins and cash flow fail to inflect.
PE
87.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute: Boeing's debt-to-equity of 9.98x and total debt at 88.3% of capitalization mean interest expense of $600M per quarter consumes cash, while the quick ratio of 0.33 and current ratio of 1.19 leave thin liquidity. Free cash flow remains negative on a trailing basis (-$210M TTM) despite the Q2 2026 positive inflection of +$631M, and gross margin compressed to 9.83% in Q2 from 11.46% in Q1, showing margin recovery is not yet durable. Revenue concentration in Commercial Airplanes ($11.75B of $24.56B) ties the thesis to delivery ramp execution, and the 7.96% YoY growth rate provides little buffer if MAX 10 certification benefits slip.
Market and competitive risks center on valuation compression: the 50.1x forward PE and 28.4x EV/EBITDA sit at a premium to mature aerospace primes in the mid-to-high teens, leaving the stock vulnerable to any earnings disappointment. With a beta of 1.257, Boeing is roughly 26% more volatile than the market, amplifying drawdowns in risk-off environments, and its -26.64% one-year relative strength versus SPY highlights persistent underperformance. Competitive pressure from Airbus and SpaceX, plus regulatory scrutiny following the MAX 10 certification process, could delay the delivery ramp and keep multiples compressed.
The worst-case scenario is a chain of events where MAX 10 ramp execution stumbles, gross margins fail to recover above 10%, and free cash flow turns negative again, forcing additional debt raises at high rates. In that scenario, the stock could retest its 52-week low of $176.77, roughly 6.1% below the current $188.35, and a breakdown below that level could open a new leg lower toward the analyst low target of $206 (which is above current price but represents a downside scenario if estimates are cut). A more severe outcome, consistent with the -26.87% max drawdown, would imply a price near $137.7, or about -27% from current levels, if the turnaround thesis fully unwinds.
FAQ
The most severe risk is financial: debt-to-equity of 9.98x, a quick ratio of 0.33, and interest expense of $600M per quarter leave little liquidity cushion, and free cash flow remains negative on a trailing basis (-$210M TTM). Second is execution risk on the MAX 10 delivery ramp, with gross margin already compressed to 9.83% in Q2 2026. Third is valuation compression: the 50.1x forward PE and 28.4x EV/EBITDA could de-rate if earnings recovery stalls. Fourth is competitive pressure from Airbus and SpaceX, plus regulatory scrutiny. With a beta of 1.257, the stock is 26% more volatile than the market, amplifying drawdowns.
The 12-month forecast has three scenarios: a bull case (25% probability) targeting $267–$305 if MAX 10 ramp accelerates and margins recover to mid-teens; a base case (50% probability) targeting $206–$267 with gradual improvement and free cash flow near breakeven; and a bear case (25% probability) targeting $176.77–$206 if execution stumbles and margins stay below 10%. The base case is most likely, assuming revenue growth of 7-9% and gross margin recovery to 10-12%. The key assumption is that MAX 10 certification translates into a smooth delivery ramp without further regulatory or labor disruptions.
BA is fairly valued to slightly overvalued on current fundamentals but undervalued relative to its own history and analyst targets. The trailing PE of 87.2x is distorted by near-zero earnings, while the forward PE of 50.1x and EV/EBITDA of 28.4x represent a premium to mature aerospace primes in the mid-to-high teens. The PS ratio of 1.85x is not extreme, but the price-to-cash-flow of 155.4x underscores how far cash generation must improve. The market is pricing in a recovery to FY EPS of $14.56, so any disappointment could compress multiples. Relative to its multi-year PS range, the stock appears near the low end, suggesting pessimism is priced in, but the premium to peers means it is not cheap on absolute terms.
From a risk/reward perspective, BA offers 41.9% upside to the analyst average target of $267.22, but the downside to the 52-week low of $176.77 is only 6.1%, creating an asymmetric setup for patient investors. However, the stock trades at a 50.1x forward PE and carries 9.98x debt-to-equity, so it is not a low-risk buy. The biggest downside risk is a delay in the MAX 10 ramp that keeps margins below 10% and free cash flow negative. For risk-tolerant investors with a 2-3 year horizon, the current price near $188 could be an attractive entry, but conservative investors should wait for evidence of sustained margin recovery above 12%.
BA is better suited for long-term investment (minimum 2-3 years) because the turnaround thesis depends on the MAX 10 delivery ramp and margin recovery materializing by 2027. The stock's beta of 1.257 and -26.87% max drawdown make it too volatile for short-term trading, and the negligible dividend yield of 0.20% offers no income support. Earnings visibility is low given quarterly losses, so short-term traders face event risk from earnings and certification news. A patient investor with a 3-year horizon could capture the recovery, but should size positions to account for amplified drawdowns.